This inventor holds 5 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Medigenebio Corporation, The Green Cross Corporation, Korea Greencross Corporation. Active years: 2005-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
4 out of 7 
4 out of 264 
1 out of 16 Years Active: 2005-2019
Title: The Innovations of Sang Hoon Paik in Genetic Therapy
Introduction
Sang Hoon Paik, hailing from Yongin-si, South Korea, is an accomplished inventor known for his significant contributions to the field of genetic therapy. With a total of five patents to his name, his work focuses on advancements that offer new therapeutic options for rare genetic disorders, particularly Hunter Syndrome.
Latest Patents
One of Sang Hoon Paik's latest patents revolves around a composition and formulation that comprises recombinant human iduronate-2-sulfatase (IDS). This patent presents a method for producing a purified recombinant IDS, which differs in glycosylation patterns and formylglycine content from existing treatments like ELAPRASE®. As a result, this innovative formulation boasts superior pharmaceutical efficacy and safety compared to conventional agents, making it a promising option for the therapy of Hunter Syndrome.
Career Highlights
Throughout his professional journey, Sang Hoon Paik has collaborated with notable companies in the biotechnology sector, such as the Green Cross Corporation and Medigenebio Corporation. His extensive experience in these organizations has contributed to his expertise and success as an inventor in genetic therapies.
Collaborations
In addition to his work at various companies, Sang Hoon Paik has also partnered with esteemed colleagues such as Thong-Gyu Jin and Yo Kyung Chung. These collaborations have further enriched his research and innovation efforts in creating impactful therapeutic solutions.
Conclusion
Sang Hoon Paik continues to be a pioneering force in the field of genetic therapy, with his inventions paving the way for enhanced treatments for rare diseases. His dedication to innovation and collaboration highlights the importance of combining scientific talent with practical applications, ultimately improving the lives of patients suffering from genetic disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile